Is there a growth of the pharma sector in India? Considering the various issues the industry is facing, the future does not look bright. While on the one hand some key domestic players are selling their core brands to overseas buyers or to some domestic based MNCs and looking at investing in research and development, there are several issues that are causing a bit of anxiety.
Starting with the clinical trial activities, USFDA’s stringent measures on the domestic generic drug makers, and regulation of National Pharmaceutical Pricing Policy affecting both the domestic and multinationals in India, some of the key players have begun exiting the area. The current regulatory restrictions on the clinical trial front has resulted in many of the leading MNC pharma players to wind up operations and shift the activity to other countries.